Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | ITPR3 | Q14573 | 1/20 | 0.35 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28365879 | 0.92 | LPAR3 (0.43) | LPAR3LPAR2LPAR1PPARDITPR3 | |
| SCHEMBL15974123 | 0.91 | LPAR3 (0.48) | LPAR3LPAR2LPAR1 | |
| SCHEMBL11242110 | 0.89 | LPAR3 (0.33) | LPAR3LPAR2LPAR1PPARDITPR3 | |
| SCHEMBL18015062 | 0.89 | ITPR3 (0.41) | LPAR3LPAR2LPAR1ITPR3ITPR1 | |
| SCHEMBL15250606 | 0.89 | LPAR3 (0.47) | LPAR3LPAR2LPAR1PPARDCYP3A4 | |
| SCHEMBL16559184 | 0.85 | LPAR3 (0.39) | LPAR3LPAR2LPAR1PPARDITPR3 | |
| SCHEMBL700912 | 0.85 | LPAR3 (0.34) | LPAR3LPAR2LPAR1PPARDITPR3 | |
| SCHEMBL1652763 | 0.85 | BTN3A1 (0.52) | LPAR3LPAR2LPAR1BTN3A1 | |
| SCHEMBL27864077 | 0.85 | LPAR3 (0.34) | LPAR3LPAR2LPAR1PPARDITPR3 | |
| SCHEMBL27864078 | 0.85 | LPAR3 (0.34) | LPAR3LPAR2LPAR1PPARDITPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744113-A2 | ELECTRODES FOR ENERGY STORAGE DEVICES | Nanoramic, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12629426-B2 | Muscle targeting complexes and uses thereof for treating dystrophinopathies | DYNE THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12624120-B2 | Anti-transferrin receptor (TfR) antibody and uses thereof | DYNE THERAPEUTICS, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260034230-A1 | COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR (TFR)-MEDIATED DELIVERY TO THE BRAIN AND MUSCLE | REGENERON PHARMACEUTICALS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4673544-A1 | METHODS AND COMPOSITIONS FOR INHIBITING PROGRESSION OF INTRAMUSCULAR FIBROSIS | Dyne Therapeutics, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250382375-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | DYNE THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12496352-B2 | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | DYNE THERAPEUTICS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| EP-4654982-A1 | MODIFIED RHABDOVIRUS GLYCOPROTEINS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250360223-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | DYNE THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | US | disclosed |
| US-12478687-B2 | United states | DYNE THERAPEUTICS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20010003618-A1 | POLYESTER FIBER AND FABRICS MADE BY USING THE SAME | ASAHI KASEI KOGYO KABUSHIKI KAISHA | 2001-06-14 | — | — | US | disclosed |
| EP-1032433-A2 | STERILIZATION WRAP, APPLICATIONS THEREFOR, AND METHOD OF STERILIZING | Kimberly-Clark Worldwide, Inc. (US) | 2000-09-06 | — | — | EP | disclosed |
| EP-1016741-A1 | POLYESTER FIBER AND FABRICS MADE BY USING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 2000-07-05 | — | — | EP | disclosed |
| EP-1016692-A1 | POLYESTER RESIN COMPOSITION | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999022635-A2 | STERILIZATION WRAP, APPLICATIONS THEREFOR, AND METHOD OF STERILIZING | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| US-5700923-A | RIGID LINKER COMPRISING AT LEAST ONE NON-NUCLEOTIDIC UNIT, FLANKED BY FIRST AND SECOND FLANKING REGIONS OF AT LEAST FOUR CONTIGUOUS, COVALENTLY-LINKED NUCLEOTIDES; COMPLEMENTARY TO TARGET REGION ON SUBSTRATE RNA MOLECULE | HYBRIDON, INC. (US) | 1997-12-23 | — | — | US | disclosed |
| US-5679554-A | LINKING A CYCLOHEXANEDIOL, A STEROID, A LUPENEDIOL OR ISOSORBIDE TO FLANKING REGIONS OF A RIBOZYME HAVING AN ENDONUCLEOLYTICALLY ABILITY TO CLEAVE RNA; INCREASED NUCLEASE RESISTANCE; HALF-LIVES; ANTISENSE OLIGONUCLEOTIDES | HYBRIDON, INC. (US) | 1997-10-21 | — | — | US | disclosed |
| US-5650502-A | Ribozyme analogs having rigid non-nucleotidic linkers | HYBRIDON, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| US-5646021-A | CLEAVAGE OF RNA | HYBRIDON, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1995006764-A2 | OLIGONUCLEOTIDES WITH RNA CLEAVAGE ACTIVITY | VPI HOLDINGS LTD. (BM) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624120-B2 | Anti-transferrin receptor (TfR) antibody and uses thereof | FTH1, TFRC, VSIG8 | LPAR3 3681/4885LPAR2 3522/4885LPAR1 3893/4885 |
| US-20250382375-A1 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF | MUSK, MYOF, MYLK2 | LPAR3 1876/4885LPAR2 1525/4885LPAR1 2044/4885 |
| US-20260034230-A1 | COMPOSITIONS AND METHODS FOR TRANSFERRIN RECEPTOR (TFR)-MEDIATED DELIVERY TO THE BRAIN AND MUSCLE | MUSK, TFRC, MYOF | LPAR3 1445/4885LPAR2 631/4885LPAR1 1385/4885 |
| US-20250360223-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | UTRN, MUSK, MYOF | LPAR3 2381/4885LPAR2 2131/4885LPAR1 2384/4885 |
| US-12496352-B2 | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | MUSK, MYOF, MYLK2 | LPAR3 1832/4885LPAR2 1717/4885LPAR1 2184/4885 |
| US-12478687-B2 | United states | UTRN, MUSK, SMN1; SMN2 | LPAR3 2517/4885LPAR2 2364/4885LPAR1 2287/4885 |
| US-12629426-B2 | Muscle targeting complexes and uses thereof for treating dystrophinopathies | MYOF, MUSK, UPF1 | LPAR3 4047/4885LPAR2 3635/4885LPAR1 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.